Silence Therapeutics plc (SLN) — Financial statements
Income statement, balance sheet, and cash flow for Silence Therapeutics plc — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.56↓98.7% | 43↑70.5% | 25↑17.2% | 22↑74.4% | 12 | |
| Cost of Revenue | 0.22↓98.2% | 12↑14.5% | 10↓23.4% | 13↑80.6% | 7 | |
| Gross Profit | 0.34↓98.9% | 31↑108.9% | 15↑83.8% | 8↑65.2% | 5 | |
| Operating Expenses | ||||||
| R&D Expenses | 68↓0.2% | 68↑54.2% | 44↑1.1% | 44↑41.6% | 31 | |
| General & Administrative Expenses | 22↓16.9% | 27↑30.3% | 21↓19.6% | 26↑28.4% | 20 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 22↓16.9% | 27↑30.3% | 21↓19.6% | 26↑28.4% | 20 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 90↓4.9% | 95↑46.6% | 65↓6.6% | 69↑36.4% | 51 | |
| Total Costs & Expenses | 90↓15.3% | 107↑42.1% | 75↓9.3% | 83↑42.0% | 58 | |
| Operating Results | ||||||
| Operating Income | -90↓41.7% | -63↓27.6% | -50↑18.7% | -61↓33.2% | -46 | |
| Depreciation & Amortization | 0.56↓6.4% | 0.59↑19.1% | 0.50↓16.4% | 0.60↑39.6% | 0.43 | |
| EBITDA | -89↓82.1% | -49↑1.6% | -50↑17.6% | -60↓33.1% | -45 | |
| EBIT | -90↓81.0% | -50↑1.4% | -50↑17.6% | -61↓33.1% | -46 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↓22.2% | 4↑216.7% | 1↑688.8% | 0.18↑8850.0% | 0.00 | |
| Interest Income | 3↓22.2% | 4↑209.3% | 1↑539.8% | 0.23↑2160.0% | 0.01 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 0.03↓27.7% | 0.05↑487.5% | 0.01 | |
| Non-Operating Income | 0.00↑100.0% | -14↓2144.2% | 0.67↑108.3% | -8↓23992.1% | 0.03 | |
| Other Income / Expenses | 1↓93.9% | 19↑2770.7% | -0.71↓106.2% | 11↑27228.6% | -0.04 | |
| Income Before Tax | -89↓99.3% | -44↑11.6% | -50↓1.3% | -50↓8.3% | -46 | |
| Income Tax Expense | 0.01↓98.7% | 0.85↑112.0% | -7↓1123.7% | 0.69↑110.7% | -6 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -89↓95.6% | -45↓4.7% | -43↑14.0% | -50↓27.7% | -39 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -89↓95.6% | -45↓4.7% | -43↑14.0% | -50↓27.7% | -39 | |
| Bottom-Line Net Income | -89↓95.6% | -45↓4.7% | -43↑14.0% | -50↓27.7% | -39 | |
| EPS (Basic) | -1.89↑20.3% | -2.37↑31.9% | -3.48↑7.9% | -3.78↓180.0% | -1.35 | |
| EPS (Diluted) | -1.89↑20.3% | -2.37↑31.9% | -3.48↑7.9% | -3.78↓180.0% | -1.35 | |
| Weighted Average Shares | 47↑206.4% | 15↑24.7% | 12↑15.2% | 11↓63.8% | 30 | |
| Weighted Average Diluted Shares | 47↑206.4% | 15↑24.7% | 12↑15.2% | 11↓63.8% | 30 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.